[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-362843-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-362843-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","ccl-chemokines-as-prognostic-and-immunotherapeutic-markers-in-prostate-cancer-a-comprehensive-analysis","CCL chemokines as prognostic and immunotherapeutic markers in prostate cancer - a comprehensive analysis","","Objective: delineate the prognostic significance of CCL family expression in prostate cancer (PCa) and explore immunomodulatory roles to assess therapeutic potential. Methods: derive CCL expression profiles using ONCOMINE, assess associations with pathological stage and Gleason score, and analyze genetic alterations and protein-protein interactions. Build transcriptional regulatory networks via TRRUST, evaluate immune-cell infiltration patterns, perform GO/KEGG pathway analysis, and verify CCL expression by in vitro PCR. Results identify CCL11/14/16/18/19 upregulation and CCL2/7/8/17/23/25 downregulation in PCa, with survival and clinicopathologic associations. Conclusions: support CCL chemokines as immunotherapeutic targets and prognostic biomarkers.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/ccl-chemokines-as-prognostic-and-immunotherapeutic-markers-in-prostate-cancer-a-comprehensive-analysis/362843/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/ccl-chemokines-as-prognostic-and-immunotherapeutic-markers-in-prostate-cancer-a-comprehensive-analysis/362843.png","ImageObject",300,407,{"name":42,"@type":43},"วิน","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-10-23","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",8,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What is the main objective of the study on CCL chemokines in prostate cancer?","Question",{"text":63,"@type":64},"The study aims to clarify the prognostic value of CCL family expression in prostate cancer and investigate their immunomodulatory roles to evaluate therapeutic potential.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How were CCL expression profiles identified and validated?",{"text":68,"@type":64},"CCL family expression profiles were obtained from the ONCOMINE database and validated using UALCAN, with defined statistical thresholds for significance.",{"name":70,"@type":61,"acceptedAnswer":71},"Which CCL genes showed altered expression in prostate cancer compared with normal tissues?",{"text":72,"@type":64},"The study reports increased expression of CCL11/14/16/18/19 in prostate cancer, while CCL2/7/8/17/23/25 were significantly decreased versus normal tissues.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},362843,1790940704,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,114,119,122,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":112,"slug":113},30,"research-report",{"id":115,"doc_module":4,"doc_module_name":25,"category_name":116,"show_sort_weight":117,"slug":118},9,"Religion & Spirituality",20,"religion-spirituality",{"id":117,"doc_module":4,"doc_module_name":25,"category_name":120,"show_sort_weight":117,"slug":121},"World Cup","world-cup",{"id":123,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":123,"slug":125},10,"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":55,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},2336475104736,"https://ap-avatar.wpscdn.com/avatar/22000c4c5e0e5b17e70?x-image-process=image/resize,m_fixed,w_180,h_180&k=1786591360781797222","Bai etal. World Journal of Surgical Oncology (2026) 24:144  \n[https://doi.org/10.1186/s12957-026-04265-y](https://doi.org/10.1186/s12957-026-04265-y)  \nWorld Journal of Surgical Oncology  \nRESEARCH Open Access  \nCCL chemokines as prognostic   \nand immunotherapeutic markers in prostate cancer: a comprehensive analysis  \nYao Bai 1, Chaojin Liang 1, Jie Gu2, LuoWu Wang 1 and KeYang 1*  \nAbstract  \nObjective This study aimed to delineate the prognostic significance of CCL family expression in Prostate Cancer (PCa) and explore their immunomodulatory roles to assess therapeutic potential.  \nMethods We identified CCL family expression profile utilizing ONCOMINE, and their relationship with the pathological stage and Gleason Score of PCa patients. The genetic alterations and protein-protein interactions were investigated in PCa. Subsequently, Transcriptional regulatory networks were established using TRRUST database. The immunocyte infiltration expression profile was investigated based on the CCL expression. Go and KEGG analysis was employed to further explore the biological functions and pathways. Finally, we verified the CCL gene expression using in vitro PCR experiments.  \nResults The findings revealed a notable elevation in the expression levels of CCL11/14/16/18/19 in PCa, whereas the expression of CCL2/7/8/17/23/25 were significantly decreased in PCa compared to the expression levels in normal tissues. High expression of both CCL3 and CCL4 was significantly associated with shorter disease-free survival. CCL8/22/24 and CCL3/11/17/18/19/22 was associated with high pathological N stage and high Gleason Score, respectively. High expression of CCL11/17/18/22/24 and CCL3/11/17/18/19/22 was associated with high pathological N stage and high Gleason Score, respectively.  \nConclusions The findings may provide insights and evidence on the potential application of CCL chemokines as immunotherapeutic treatment targets and prognostic biomarkers for PCa.  \nKeywords Prostate cancer, CCL chemokines, prognostic biomarkers, bioinformatics analysis, Immune infiltration  \nYao Bai and Chaojin Liang contributed equally as co-first authors.  \n*Correspondence: Ke Yang [yk780218@163.com](yk780218@163.com)  \n1Department of Urology, Hunan Provincial People’s Hospital, The first affiliated hospital of Hunan Normal university, Changsha 410005, China 2Department of Urology, The Second Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China  \n© The Author(s) 2026. Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit [http://creati](http://creati)[vecommons.org/l](vecommons.org/l)icenses/by-nc-nd/4.0/.  \nBai et al. World Journal of Surgical Oncology (2026) 24:144  \nIntroduction  \nProstate cancer (PCa) is one of the most prevalent and deadly cancers globally, which primarily affects older men. With approximately 1.1 million patients diagnosed annually, PCa is the fifth leading cause of cancer-related death in men worldwide [1]. Chronic inflammation and inflammatory factors, such as C-C motif chemokine ligand (CCL), play a vital role in the","cbCaigJSw1H8Xg6u","https://ap.wps.com/l/cbCaigJSw1H8Xg6u","pdf",4176639,15,"English","# Abstract\n# Introduction\n# Materials and methods","[{\"question\":\"What is the main objective of the study on CCL chemokines in prostate cancer?\",\"answer\":\"The study aims to clarify the prognostic value of CCL family expression in prostate cancer and investigate their immunomodulatory roles to evaluate therapeutic potential.\"},{\"question\":\"How were CCL expression profiles identified and validated?\",\"answer\":\"CCL family expression profiles were obtained from the ONCOMINE database and validated using UALCAN, with defined statistical thresholds for significance.\"},{\"question\":\"Which CCL genes showed altered expression in prostate cancer compared with normal tissues?\",\"answer\":\"The study reports increased expression of CCL11/14/16/18/19 in prostate cancer, while CCL2/7/8/17/23/25 were significantly decreased versus normal tissues.\"}]","CCL chemokines as prognostic and immunotherapeutic markers in prostate cancer - a comprehensive analysis | PDF",1790149189,38,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a33e69769cb9c5499623a156826c0b96.webp",983,1310,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e93897af369ba356b302433421726d2e.webp",982,1309,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/c83a795962b2fca2b7743b2c77321e7b.webp",981,1308,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7abe12b5391aed5650d8fe8bf111c01b.webp",980,1306]